Phaseline

Targets › SLC7A8

SLC7A8 (Large neutral amino acids transporter small subunit 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Associates with SLC3A2 to form a functional heterodimeric complex that translocates small and large neutral amino acids with broad specificity and a stoichiometry of 1:1. Functions as amino acid antiporter mediating the influx of extracellular essential amino acids mainly in exchange with the efflux of highly concentrated intracellular amino acids. (UniProt, Q9UHI5)

Open in Phaseline: the race on SLC7A8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Brigham and Women's Hospital18F-fluciclovine
Amino acid transporter targeting radiotracer
SLC7A5, SLC7A8Phase 1Advanced Prostate CancerSep 2027

Conditions

Advanced Prostate Cancer (1)

Modalities

small molecule (1)

Companies

Brigham and Women's Hospital (1)

Related targets

SLC7A5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.